The present invention relates to soluble organic compounds, to compositions comprising these compounds, to formulations comprising the compounds or compositions, and to electronic devices.

The present invention aims to provide a polymerizable compound that has high storage stability without causing crystal precipitation when added to a polymerizable composition and to provide a polymerizable composition containing the polymerizable compound. A polymer film produced by polymerization of the polymerizable composition has a low haze, high thickness uniformity, low occurrence of nonuniform orientation, high surface hardness, high adhesiveness, and good appearances and fewer orientation defects even after ultraviolet irradiation. The present invention also aims to provide a polymer produced by polymerization of the polymerizable composition and an optically anisotropic body produced from the polymer.

The present invention aims to provide a polymerizable compound that has high storage stability without causing crystal precipitation when added to a polymerizable composition and to provide a polymerizable composition containing the polymerizable compound. A polymer film produced by polymerization of the polymerizable composition has a low haze, high thickness uniformity, low occurrence of nonuniform orientation, high surface hardness, high adhesiveness, and good appearances and fewer orientation defects even after ultraviolet irradiation. The present invention also aims to provide a polymer produced by polymerization of the polymerizable composition and an optically anisotropic body produced from the polymer.

An organic light-emitting device includes a first electrode, a second electrode facing the first electrode, and an organic layer disposed between the first electrode and the second electrode, the organic layer including an emission layer, a hole transport region between the first electrode and the emission layer, and an electron transport region between the emission layer and the second electrode, wherein the electron transport region includes a first layer that includes a metal oxide and a metal halide, and wherein the first layer is not in direct contact with the emission layer.

An organic light-emitting device includes a first electrode, a second electrode facing the first electrode, and an organic layer disposed between the first electrode and the second electrode, the organic layer including an emission layer, a hole transport region between the first electrode and the emission layer, and an electron transport region between the emission layer and the second electrode, wherein the electron transport region includes a first layer that includes a metal oxide and a metal halide, and wherein the first layer is not in direct contact with the emission layer.

A compound having a metal coordination complex structure, where the compound is capable of functioning as a phosphorescent emitter in an organic light emitting device at room temperature is disclosed. The compound has a first ligand coordinated to a metal. The free-state of the first ligand has a first triplet energy T1 of E.sub.L at 77K, while the compound has a first triplet energy T1 of E at 77K, and the difference in energy (ΔE) between E and E.sub.L is ≤250 meV. The compound has a triplet emission spectrum with a FWHM value of no more than 45 nm. Organic light emitting devices, consumer products, and formulations containing the compounds are also disclosed.

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R.sub.1a, R.sub.1b, R.sub.2a, R.sub.2b, R.sub.3, R.sub.4, R.sub.5a, R.sub.5b, R.sub.6a, R.sub.6c, R.sub.7a, R.sub.7b, R.sub.7c, and R.sub.7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

##STR00001##

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R.sub.1a, R.sub.1b, R.sub.2a, R.sub.2b, R.sub.3, R.sub.4, R.sub.5a, R.sub.5b, R.sub.6a, R.sub.6c, R.sub.7a, R.sub.7b, R.sub.7c, and R.sub.7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

##STR00001##

A condensed cyclic compound represented by Formula 1:

##STR00001##

wherein, in Formula 1, groups and variables are the same as described in the specification.

A condensed cyclic compound represented by Formula 1:

##STR00001##

wherein, in Formula 1, groups and variables are the same as described in the specification.